Friends of Cancer Research has launched a collaboration that aims to address concerns about the lack of consistency in determining homologous recombination deficiency—HRD—status, its prognostic value, and its use as a predictive biomarker.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe